Longitudinal Trajectory of Opioid Prescribing and its Associated Serious Adverse Events: A Population‐Wide Cohort Study in Taiwan
Clinical Pharmacology & Therapeutics · 2023
DOI: 10.1002/cpt.3058 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Teng-Chou Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Tramadol, Chronic Pain. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Chronic opioid prescribing (COP) for noncancer pain is highly restricted in Taiwan, but tramadol is not listed in the regulation on chronic prescribing. This study investigated the trajectories of COP in noncancer pain when considering tramadol in Taiwan and identified the risk of serious adverse events. This population‐wide longitudinal cohort study used the Taiwan National Health Insurance claims records from 2001 to 2016. Adults prescribed opioids (including tramadol) and without cancer were selected. Patients who received COP (opioid supply days for 28 days or continuous opioid supply for 14 days) in the first patient quarter were included, and serious adverse events were identified. Group‐based trajectory models were applied to identify patients with a similar trajectory of quarterly COP. The Cox proportional hazard model was applied to assess the association between adverse events and patients' trajectories. Of the 2,360,358 noncancer opioid users, 476,934 (20.2%) received COP in the first quarter. Four groups of COP trajectory were identified, and 59,310 (12.8%) patients received COP quarterly over 2 years. Patients categorized into the trajectory of long‐term COP had a significantly higher crude incidence rate of cardiovascular death, seizure, and hypoglycemia. Still, there is no newly developed opioid use disorder. There was a substantial underestimate in COP in Taiwan when tramadol was not considered. Notably, 10% of them could receive COP for over 2 years. The result raises concern about unmet pain management needs and the limited accessibility of alternative treatments for noncancer pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK.
- Department of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Anesthesiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Health Data Research Center, National Taiwan University, Taipei, Taiwan.
- NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
ORCID-Profile: Teng-Chou Chen, Chih-Peng Lin, Darren M Ashcroft, K Arnold Chan, Li-Chia Chen
Zitieren
APA
Chen, T. C., Lin, C. P., Wang, T. C., Ashcroft, D. M., Chan, K. A., & Chen, L. C. (2023). Longitudinal Trajectory of Opioid Prescribing and its Associated Serious Adverse Events: A Population‐Wide Cohort Study in Taiwan. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3058
Vancouver
Chen TC, Lin CP, Wang TC, Ashcroft DM, Chan KA, Chen LC. Longitudinal Trajectory of Opioid Prescribing and its Associated Serious Adverse Events: A Population‐Wide Cohort Study in Taiwan. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3058
BibTeX
@article{Chen2023,
author = {Chen, Teng-Chou and Lin, Chih-Peng and Wang, Ting-Chun and Ashcroft, Darren M and Chan, K Arnold and Chen, Li-Chia},
title = {Longitudinal Trajectory of Opioid Prescribing and its Associated Serious Adverse Events: A Population‐Wide Cohort Study in Taiwan},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
doi = {10.1002/cpt.3058}
}
EUVIMED